All Oncology News

Jane L. Meisel, MD, highlighted patient-reported gaps in provider communication regarding treatment-related toxicities in metastatic breast cancer.

Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.

Soquelitinib has been granted an orphan drug designation by the FDA for potential use in T-cell lymphoma.

Apalutamide plus androgen deprivation therapy improved prostate-specific antigen progression-free survival in castration-sensitive prostate cancer.

The EMA is evaluating a Type II extension of indication application for the approval of first-line amivantamab plus lazertinib in EGFR-mutated NSCLC.

Florida Cancer Specialists & Research Institute announces their intentions to explore a new distributor and group purchasing organization partnerships.

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.

NXC-201 has received orphan drug designation from the European Commission for use in patients with amyloid light-chain amyloidosis.

The phase 3 ENHANCE-3 study of magrolimab plus venetoclax/azacitidine vs venetoclax/azacitidine in select patients with AML has been terminated.

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.

Teclistamab produced responses in real-world patients with relapsed and refractory multiple myeloma and prior exposure to BCMA-targeted therapy.

The Tulane Transplant Institute offers comprehensive disease management for patients with end-stage organ disease of the kidney, liver, and pancreas.

HPN328, was well tolerated and elicited responses in patients with neuroendocrine prostate cancer and other neuroendocrine neoplasms.

Dhruva explains how physicians reported a lack of understanding when it comes to the FDA approval process, especially regarding expedited approval pathways.

Hyperthermic intraperitoneal chemotherapy plus interval cytoreductive surgery improved progression-free survival in stage III epithelial ovarian cancer.

The NCCN Breast Cancer Panel has included goserelin at 2 dosing schedules as a method for ovarian function suppression in their updated guidelines.

Identifying biomarkers and the mechanism of action of antibody-drug conjugates may optimize benefits with these agents in non–small cell lung cancer.

Survival outcomes following curative resection in resectable NSCLC have been poor and, until recently, the main tool oncologists had at their disposal was neoadjuvant or adjuvant chemotherapy.

Balazs Halmos, MD, discusses the FLAURA2 and MARIPOSA trials of EGFR TKIs plus chemotherapy in EGFR-mutated non–small cell lung cancer.

Huntsman Cancer Institute introduces the first and only single-port robot in the Mountain West for head and neck surgical oncology patients.

The FDA and EMA have accepted applications seeking the approval of neoadjuvant nivolumab/chemotherapy followed by surgery and adjuvant nivolumab in NSCLC.

Edgardo S. Santos Castillero, MD, FACP, spotlights some impactful trials in lung cancer that were discussed in 2023, including the phase 3 MARIPOSA-2 trial, and more.

The University of Hawaii Cancer Center hopes to address treatment needs through its planned Early Phase Clinical Research Center.

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

Fruquintinib/paclitaxel significantly improved PFS but not OS vs paclitaxel alone in the second-line treatment in patients with advanced gastric cancer.

Thomas J. Lynch Jr, MD, details how treatments are evolving for patients with EGFR-mutated advanced non–small cell lung cancer.

Corey J. Langer, MD, FACP, discusses findings from the IMpower010 and KEYNOTE-091 studies, which examined immunotherapy in NSCLC.

Vepdegestrant has received FDA fast track designation for select patients with ER-positive/HER2-negative locally advanced or metastatic breast cancer.

The National Accreditation Program for Breast Centers has granted the Florida Cancer Specialists & Research Institute breast cancer program a 3-year accreditation.

Investigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.